Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03690505
Other study ID # I16027/DEMELE
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 12, 2019
Est. completion date January 1, 2021

Study information

Verified date June 2019
Source University Hospital, Limoges
Contact Catherine Catherine DE SOUSA, Nurse
Phone 05 55 05 64 79
Email InfirmieresConsultOphtalmo@chu-limoges.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for "straight-ahead" activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail

The purpose of the study is to describe in patients with AMD and depending on the nature of their pathology (neovascular or atrophic):

(i) knowledge about their pathology (risk factors, symptoms, treatments, self-monitoring tool), (ii) their needs and (iii) impact on their daily lives

This study is to make an inventory of the knowledge of patients with AMD about their disease and risk factors using a questionnaire (Appendix 1) and to identify their needs, the impact of the disease on their daily lives during individual interviews by raising the recurrent data and confronting them during the focus group. The information gathered will enable the construction of a therapeutic education program for better patient care and to strengthen the patient's capacities so that he becomes an actor in his change throughout his care project.

This a 3 steps study:

1. 200 patients will be enrolled and answer a questionnaire on knowledge of the disease

2. Two groups of 20 patients will be selected to participate to a semi-structured individual interviews

3. Two focus groups of 10 patients will be organized to assess needs, expectations, satisfactions or to better understand opinions, motivations or behaviors.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 1, 2021
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 50 Months and older
Eligibility Inclusion Criteria:

- Patient with AMD (neovascular and atrophic) whatever the stage of the disease

- Patient over 50

- Patient affiliated to a social security scheme

- Written informed consent of the patient

Exclusion Criteria:

- Patient unable to understand the information, fill out the questionnaires

- Patient with diabetic retinopathy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Interviews
informant-based questionnaire semi-structured individual interviews focus group interviews

Locations

Country Name City State
France Service d'Ophtalmologie Limoges

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Knowledge of AMD Assesment concern patients knowledge of AMD disease, the treatment of AMD, the diagnostic of AMD and the knowledge on the AMD risk factors A 12 items standardised questionnaire will be used throughout the study, 2 years at maximum
Primary Social vulnerability Assessed by EPICES scale (Evaluation of Precariousness and Health Inequalities in the Health Examination Centers). It is an individual indicator of precariousness that takes into account the multidimensional nature of precariousness. Compsed of 11 items . 4 unfavorable answers indicate a Social vulnerability throughout the study, 2 years at maximum
Secondary Health literacy. Assessed by the Health Literacy Questionnaire (HLQ) scale. It has nine scales that each measure an aspect of the multidimensional construct of health literacy.
Higher scores assess for an good health literacy
throughout the study, 2 years at maximum
See also
  Status Clinical Trial Phase
Completed NCT01694680 - Intervention Trial in Early Age-related Macular Degeneration N/A
Completed NCT01224847 - Intravitreal Injection Anesthesia - Comparison of Different Topical Agents N/A
Withdrawn NCT04697953 - Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) Phase 3
Completed NCT05037396 - Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
Completed NCT00647439 - Genetics and Markers of Degenerative and Inflammatory Eye Diseases
Terminated NCT00902785 - A Study Of Early Markers Of Choroidal Neovascularization Phase 4
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Recruiting NCT03577041 - Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Completed NCT05082415 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
Completed NCT02445313 - Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
Recruiting NCT00354445 - A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD Phase 4
Completed NCT05111743 - Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
Terminated NCT02398500 - Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT05110209 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Completed NCT05146687 - Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Not yet recruiting NCT05780931 - Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
Recruiting NCT04292080 - Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02022540 - Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD Phase 1
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A